BioCentury
ARTICLE | Clinical News

Atrix reports preliminary Phase III Atrigel data

January 19, 2000 8:00 AM UTC

Preliminary data from 36 patients with advanced prostate cancer in an ongoing Phase III study showed that leuprolide delivered via ATRX's Atrigel delivery technology reduced testosterone levels. The p...